Key therapeutic categories

  • Dermatology
  • Cardiac
  • Respiratory
  • Anti-Infective
  • Anti-diabetic

Glenmark has been operating in the Indian market since its inception in 1977. We are leading player in India, with a robust portfolio of branded generic products. Since our inception, Glenmark has launched over 320 products in the Indian market. We have consistently been ranked among the Top 20 fastest growing companies in the Indian pharmaceutical market. In our key therapy categories in India, we ranked second in dermatology, sixth in respiratory and eight in cardiovascular.

Glenmark’s strategy has been to capitalize on the first-mover advantage by making an early entry to new high-growth therapy segments, which is driven by developing strong brands across core therapy categories, and the introduction of new products on a regular basis. In India, our branded formulations business focuses on high growth and large therapy categories such as dermatology, respiratory, cardiovascular, anti-diabetic and oncology. We are also present in some of the other therapy categories such as gynaecology, anti-infective and gastroenterology. To strengthen our branded formulations business in India, we have organised our branded formulations business into multiple divisions which focus on select therapy categories with a team of more than 3,700 medical marketing representatives. In addition to the prescription business, Glenmark also has an upcoming OTC business with some strong brands like VWash and Candid powder in their product portfolio.